Corvus Pharmaceuticals (C17) Q2 2026 Earnings Report

The call presents a largely positive development picture driven by a strong cash position, promising Phase 1 atopic dermatitis efficacy and safety signals, multiple planned trials across indications, and defined near-term catalysts (Angel cohort data, SEERA-1 topline, PTCL interim). These positives are tempered by substantially higher R&D spend and widening net losses, increased stock-based compensation, and clinical/regulatory execution risks (including a futility analysis and reliance on partner timelines). On balance the clinical progress and cash runway meaningfully outweigh the financial and execution risks in the near term.

Management provided detailed financial and clinical guidance: Q2 2026 R&D expense was $16.0M (vs $7.9M in Q2 2025) and net loss was $18.0M (vs $8.0M), with noncash equity‑method losses of $0.7M in Q2 2026 (vs $0.4M) and a $2.0M noncash warrant gain in Q2 2025, stock‑based compensation of $2.6M (vs $1.3M); cash and marketable securities totaled $215M as of 6/30/2026 (vs $56.8M at 12/31/2025) including ~ $189M net proceeds from a Q1 follow‑on, Corvus invested $5M in Angel’s $13.5M financing, and they expect cash to fund operations into Q2 2028. Clinical guidance and timelines: Phase III PTCL will enroll ~150 patients randomized 1:1 (Soquelitinib vs SOC belinostat/pralatrexate) with background median PFS ≈3 months, a planned futility analysis after a predefined number of PFS events expected in Q1 2027 and final data projected late 2027; AD data showed in Phase 1 cohort 4 (N=24, 56‑day 200 mg BID) 75% EASI‑70 vs 20% placebo, 25% EASI‑90 vs 0, and 33% IGA 0/1 vs 0; Phase II SEERA‑1 is planned to enroll ~200 patients (4 cohorts of 50: 200 mg QD, 200 mg BID, 400 mg QD + placebo), 12‑week treatment + 90‑day follow‑up with enrollment completion expected early 2027 and top‑line data in Q3 2027; Angel’s AD trial has two 24‑patient cohorts (additional 60–90 patients anticipated), cohort 1 enrollment expected complete in September with data before year‑end 2026 and cohort 2 data in Q2 2027, positioning a possible Phase III start by end‑2027; additional plans include a Phase 1b HS study (up to 25 patients, 200 mg BID for 12 weeks) starting in September and Phase II asthma trials in the US later this year and in China (Angel) in early 2027 (noting ~40–50% of asthma is non‑T2 and the asthma trial includes both T2 and non‑T2 with an interim futility analysis).